Angiogenesis: A balancing act between integrin activation and inhibition?

European Cytokine Network

Volumn 20, Issue 4, 2009, Pages 191-196

  Bussolino, Federico ^a   Caccavari, Francesca ^a   Valdembri, Donatella ^a   Serini, Guido ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Integrins; Neuropilin; Plexin; Semaphorin; Vascular endothelial growth factor

Indexed keywords

BINDING PROTEIN; CHEMOATTRACTANT; GROWTH FACTOR; GUANOSINE TRIPHOSPHATASE; INTEGRIN; NEUROPILIN; PHOSPHOTYROSINE BINDING PROTEIN; RAS PROTEIN; SCLEROPROTEIN; SEMAPHORIN; UNCLASSIFIED DRUG; VASCULOTROPIN INHIBITOR;

ANGIOGENESIS; BINDING AFFINITY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CARCINOGENESIS; CELL INTERACTION; CELL MIGRATION; ENZYME ACTIVATION; ENZYME INHIBITION; EXTRACELLULAR MATRIX; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR DYNAMICS; MORPHOGENESIS; NEOPLASM; NONHUMAN; OXYGEN DELIVERY DEVICE; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; REVIEW; SOLID TUMOR; TUMOR VASCULARIZATION;

ANIMALS; BLOOD VESSELS; HUMANS; INTEGRINS; MONOMERIC GTP-BINDING PROTEINS; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN STRUCTURE, TERTIARY; TISSUE ADHESIONS;

VERTEBRATA;

EID: 72249096538     PISSN: 11485493     EISSN: None     Source Type: Journal    
DOI: 10.1684/ecn.2009.0168     Document Type: Review

References (49)

1. Baluk P, Hashizume H, McDonald DM. Cellular abnormalities of blood vessels as targets in cancer. Curr Opin Genet Dev 2005; 15: 102-111 (Pubitemid 40127638)
2. Jain RK. Lessons from multidisciplinary translational trials on anti-angiogenic therapy of cancer. Nat Rev Cancer 2008; 8: 309-316
3. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005; 307: 58-62.
4. Jain RK. Molecular regulation of vessel maturation. Nat Med 2003; 9: 685-693
5. Serini G, Valdembri D, Bussolino F. Integrins and angiogenesis: a sticky business. Exp Cell Res 2006; 312: 651-658
6. Hynes RO, Zhao Q. The evolution of cell adhesion. J Cell Biol 2000; 150: F89-F96.
7. Hynes RO. Cell-matrix adhesion in vascular development. J Thromb Haemost 2007; 5 (Suppl. 1): 32-40.
8. Larsen M, Artym VV, Green JA, Yamada KM. The matrix reorganized: extracellular matrix remodeling and integrin signaling. Curr Opin Cell Biol 2006; 18: 463-471 (Pubitemid 44332914)
9. Arnaout MA, Goodman SL, Xiong JP. Structure and mechanics of integrin-based cell adhesion. Curr Opin Cell Biol 2007; 19: 495-507.
10. Campbell ID, Ginsberg MH. The talin-tail interaction places integrin activation on FERM ground. Trends Biochem Sci 2004; 29: 429-435
11. Kruger M, Moser M, Ussar S, et al. SILAC mouse for quantitative proteomics uncovers kindlin-3 as an essential factor for red blood cell function. Cell 2008; 134: 353-364 (Pubitemid 352010327)
12. Ma YQ, Qin J, Wu C, Plow EF. Kindlin-2 (Mig-2): a co-activator of beta3 integrins. J Cell Biol 2008; 181: 439-446
13. Montanez E, Ussar S, Schifferer M, et al. Kindlin-2 controls bidirectional signaling of integrins. Genes Dev 2008; 22: 1325-1330 (Pubitemid 351717522)
14. Moser M, Nieswandt B, Ussar S, Pozgajova M, Fassler R. Kindlin-3 is essential for integrin activation and platelet aggregation. Nat Med 2008; 14: 325-330 (Pubitemid 351347914)
15. Ling K, Schill NJ, Wagoner MP, Sun Y, Anderson RA. Movin' on up: the role of PtdIns(4,5)P(2) in cell migration. Trends Cell Biol 2006; 16: 276-284
16. Komatsu M, Ruoslahti E. R-Ras is a global regulator of vascular regeneration that suppresses intimal hyperplasia and tumor angiogenesis. Nat Med 2005; 11: 1346-1350 (Pubitemid 41752916)
17. Kinbara K, Goldfinger LE, Hansen M, Chou FL, Ginsberg MH. Ras GTPases: integrins' friends or foes? Nat Rev Mol Cell Biol 2003; 4: 767-776
18. Colicelli J. Human RAS superfamily proteins and related GTPases. Sci STKE 2004; 250: RE13.
19. Furuhjelm J, Peranen J. The C-terminal end of R-Ras contains a focal adhesion targeting signal. J Cell Sci 2003; 116: 3729-3738 (Pubitemid 37185302)
20. Hansen M, Prior IA, Hughes PE, et al. C-terminal sequences in R-Ras are involved in integrin regulation and in plasma membrane microdomain distribution. Biochem Biophys Res Commun 2003; 311: 829-838 (Pubitemid 37393393)
21. Wang B, Zou JX, Ek-Rylander B, Ruoslahti E. R-Ras contains a proline-rich site that binds to SH3 domains and is required for integrin activation by R-Ras. J Biol Chem 2000; 275: 5222-5227 (Pubitemid 30108927)
22. Prior IA, Harding A, Yan J, Sluimer J, Parton RG, Hancock JF. GTP-dependent segregation of H-ras from lipid rafts is required for biological activity. Nat Cell Biol 2001; 3: 368-375 (Pubitemid 32288444)
23. del Pozo MA, Alderson NB, Kiosses WB, Chiang HH, Anderson RG, Schwartz MA. Integrins regulate Rac targeting by internalization of membrane domains. Science 2004; 303: 839-842
24. Guan JL. Cell biology. Integrins, rafts, Rac, and Rho. Science 2004; 303: 773-774
25. Palazzo AF, Eng CH, Schlaepfer DD, Marcantonio EE, Gundersen GG. Localized stabilization of microtubules by integrin- and FAK-facilitated Rho signaling. Science 2004; 303: 836-839
26. Pereira-Leal JB, Seabra MC. The mammalian Rab family of small GTPases: definition of family and subfamily sequence motifs suggests a mechanism for functional specificity in the Ras superfamily. J Mol Biol 2000; 301: 1077-1087
27. Oertli B, Han J, Marte BM, et al. The effector loop and prenylation site of R-Ras are involved in the regulation of integrin function. Oncogene 2000; 19: 4961-4969 (Pubitemid 30808361)
28. Self AJ, Caron E, Paterson HF, Hall A. Analysis of R-Ras signalling pathways. J Cell Sci 2001; 114: 1357-1366
29. Goldfinger LE, Ptak C, Jeffery ED, Shabanowitz J, Hunt DF, Ginsberg MH. RLIP76 (RalBP1) is an R-Ras effector that mediates adhesion-dependent Rac activation and cell migration. J Cell Biol 2006; 174: 877-888 (Pubitemid 44373736)
30. Clark K, Pankov R, Travis MA, et al. A specific {alpha}5{beta} 1-integrin conformation promotes directional integrin translocation and fibronectin matrix formation. J Cell Sci 2005; 118: 291-300.
31. Kiosses WB, Shattil SJ, Pampori N, Schwartz MA. Rac recruits high-affinity integrin alphavbeta3 to lamellipodia in endothelial cell migration. Nat Cell Biol 2001; 3: 316-320 (Pubitemid 32201329)
32. Serini G, Valdembri D, Zanivan S, et al. Class 3 semaphorins control vascular morphogenesis by inhibiting integrin function. Nature 2003; 424: 391-397 (Pubitemid 36917481)
33. Guttmann-Raviv N, Shraga-Heled N, Varshavsky A, Guimaraes- Sternberg C, Kessler O, Neufeld G. Semaphorin-3A and semaphorin-3F work together to repel endothelial cells and to inhibit their survival by induction of apoptosis. J Biol Chem 2007; 282: 26294-26305 (Pubitemid 47443814)
34. Jain RK, Duda DG, Clark JW, Loeffler JS. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 2006; 3: 24-40. (Pubitemid 43108832)
35. Casanovas O, Hicklin DJ, Bergers G, Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in latestage pancreatic islet tumors. Cancer Cell 2005; 8: 299-309. (Pubitemid 41443415)
36. Lee S, Chen TT, Barber CL, et al. Autocrine VEGF Signaling Is Required for Vascular Homeostasis. Cell 2007; 130: 691-703. (Pubitemid 47268059)
37. Serini G, Ambrosi D, Giraudo E, Gamba A, Preziosi L, Bussolino F. Modeling the early stages of vascular network assembly. Embo J 2003; 22: 1771-1779 (Pubitemid 36460134)
38. Tang N, Wang L, Esko J, et al. Loss of HIF-1alpha in endothelial cells disrupts a hypoxia-driven VEGF autocrine loop necessary for tumorigenesis. Cancer Cell 2004; 6: 485-495 (Pubitemid 39469984)
39. Damon DH. Vascular endothelial-derived semaphorin 3 inhibits sympathetic axon growth. Am J Physiol Heart Circ Physiol 2006; 290: H1220-H1225.
40. Ito T, Kagoshima M, Sasaki Y, et al. Repulsive axon guidance molecule Sema3A inhibits branching morphogenesis of fetal mouse lung. Mech Dev 2000; 97: 35-45. (Pubitemid 30750556)
41. Vacca A, Scavelli C, Serini G, et al. Loss of inhibitory semaphorin 3A(SEMA3A) autocrine loops in bone marrow endothelial cells of patients with multiple myeloma. Blood 2006; 108: 1661-1667 (Pubitemid 44316135)
42. Bussolino F, Valdembri D, Caccavari F, Serini G. Semaphoring vascular morphogenesis. Endothelium 2006; 13: 81-91.
43. Bielenberg DR, Hida Y, Shimizu A, et al. Semaphorin 3F, a chemorepulsant for endothelial cells, induces a poorly vascularized, encapsulated, nonmetastatic tumor phenotype. J Clin Invest 2004; 114: 1260-1271 (Pubitemid 40385297)
44. Kruger RP, Aurandt J, Guan KL. Semaphorins command cells to move. Nat Rev Mol Cell Biol 2005; 6: 789-800.
45. Neufeld G, Kessler O. The semaphorins: versatile regulators of tumour progression and tumour angiogenesis. Nat Rev Cancer 2008; 8: 632-645
46. Serini G, Bussolino F. Common cues in vascular and axon guidance. Physiology (Bethesda) 2004; 19: 348-354 (Pubitemid 39636082)
47. Toyofuku T, Yoshida J, Sugimoto T, et al. FARP2 triggers signals for Sema3A-mediated axonal repulsion. Nat Neurosci 2005; 8: 1712-1719 (Pubitemid 41683199)
48. Garrity PA. Tinker to Evers to Chance: semaphorin signaling takes teamwork. Nat Neurosci 2005; 8: 1635-1636
49. Folkman J. Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 2007; 6: 273-286